Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility
Rhea-AI Summary
Mesoblast (Nasdaq:MESO) drew US$50 million from a five-year, non-dilutive credit facility provided by shareholder and director Dr Gregory George. Mesoblast reported US$122 million in cash at March 30, 2026.
The facility carries fixed 8% interest, a five-year interest-only period, and is secured solely by the Temcell royalty. Proceeds are intended to retire higher-cost NovaQuest debt and remove short-term obligations without encumbering material assets or intellectual property.
Positive
- US$50 million five-year non-dilutive facility from existing shareholder
- US$122 million cash as of March 30, 2026
- New credit line fixed at 8.00% per annum, below prior facilities
- Proceeds used to retire higher-cost NovaQuest debt and short-term obligations
- Five-year interest-only period improves near-term cash flow flexibility
- Facility does not encumber material assets or intellectual property
Negative
- US$50 million facility incurs fixed 8.00% annual interest expense
- Facility is secured by Temcell royalty, dedicating that cash flow stream
News Market Reaction – MESO
On the day this news was published, MESO declined 6.75%, reflecting a notable negative market reaction. Argus tracked a trough of -2.4% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $146M from the company's valuation, bringing the market cap to $2.01B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 29 | Quarterly results update | Positive | +0.8% | Quarter showed strong Ryoncil revenues, improved cash spend and solid cash balance. |
| Apr 28 | Phase 3 enrollment | Positive | +2.2% | Pivotal Phase 3 chronic low back pain trial met recruitment target with clear timeline. |
| Apr 14 | CAR platform acquisition | Positive | +7.8% | Exclusive CAR platform license to enhance MSC precision across inflammatory indications. |
| Apr 10 | IND clearance update | Positive | -2.0% | FDA IND clearance to proceed directly to registrational Ryoncil trial in DMD. |
| Apr 08 | R&D day highlights | Positive | +1.7% | R&D Day outlined plans to grow Ryoncil revenues and advance late-stage pipeline. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
MESO shares have generally reacted positively to operational and pipeline updates, with only one recent negative move on otherwise favorable news.
Key Terms
allogeneic medical
non-dilutive financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Optimized capital structure, retiring short-term maturing debt
Well-funded for commercial operations and growth pipeline
NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it drew down US
The credit-line has a fixed interest rate of
Mesoblast Chief Executive Silviu Itescu said, “Mesoblast’s balance sheet is strengthened by a favorable long-term facility with elimination of short-term high-cost debt. The facility does not encumber any of our material assets or intellectual property, enabling unrestricted entry into strategic partnerships or licensing transactions.”
About Mesoblast
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.
Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.
Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.
About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets.
About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.
Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast
References / Footnotes
- TEMCELL® HS Inj. is a registered trademark of JCR Pharmaceuticals Co. Ltd.
Forward-Looking Statements
This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
Release authorized by the Chief Executive.
For more information, please contact:
| Corporate Communications / Investors | |
| Paul Hughes | |
| T: +61 3 9639 6036 | |
| Media – Global | Media – Australia |
| Rubenstein | BlueDot Media |
| Caroline Nelson | Steve Dabkowski |
| T: +1 703 489 3037 | T: +61 419 880 486 |
| E: cnelson@rubenstein.com | E: steve@bluedot.net.au |
